Mereo BioPharma Discusses Groundbreaking Therapies for Rare Diseases at Global Healthcare Forum

Introduction to Mereo BioPharma

Mereo BioPharma is a clinic-stage biopharmaceutical company committed to the development of treatments for rare diseases. With its headquarters in London, Mereo BioPharma is focused on creating innovative therapies for conditions that have limited treatment options.

As part of their efforts to engage with the medical community, Dr. Denise Scots-Knight, the CEO of Mereo BioPharma, will participate in a Fireside Chat at the prestigious Jefferies Global Healthcare Conference. The event will take place on June 6, 2024, at 11:00 AM ET / 04:00 PM BST.

Tuning Into the Live Webcast

The presentation by Dr. Scots-Knight can be accessed through a live audio webcast. Interested parties can find the webcast in the Investors section of Mereo BioPharma's official website. For those unable to attend live, an archived replay will be available for two weeks following the event.

Highlight on Mereo BioPharma’s Key Therapeutic Candidates

Mereo BioPharma’s current focus lies in several therapeutic candidates aimed at treating rare diseases. Among these, setrusumab for treating osteogenesis imperfecta (OI) and alvelestat for severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD) are prominent.

Setrusumab is notably in the late stages of clinical trials, with Phase 3 studies completed for different age groups. In association with its partner Ultragenyx Pharmaceutical, the company anticipates significant developments and potential milestone payments.

Significant Designations and Approvals

The drug development landscape for Mereo BioPharma includes numerous designations and support from regulatory bodies. Setrusumab has received orphan designation from both the EMA and FDA, as well as PRIME designation from the EMA and pediatric disease designation from the FDA. Similarly, alvelestat has been designated as an orphan drug in the U.S. and received Fast Track designation from the FDA.

Oncology Initiatives at Mereo BioPharma

Aside from rare disease treatments, Mereo BioPharma is also focused on oncology. The company has two main product candidates in this area: etigilimab (anti-TIGIT) and navicixizumab.

Etigilimab has completed a Phase 1b/2 study focusing on safety and efficacy in combination with an anti-PD-1 across various tumor types. Navicixizumab, for late-stage ovarian cancer, has also seen positive trial outcomes, resulting in a partnership with Feng Biosciences to further its development and commercialization.

Expanding Partnerships and Global Presence

Mereo BioPharma continues to expand its global footprint through strategic partnerships, such as its licensing agreement with ReproNovo SA. This agreement aims to develop and commercialize leflutrozole, a non-steroidal aromatase inhibitor, for reproductive medicine.

Strategic alliances and collaborations are vital for Mereo BioPharma’s growth and the global availability of their innovative treatments. Through these strategic alignments, the company aims to leverage collaborative expertise and resources to advance its therapeutic pipeline.

Forward-Looking Statements

Mereo BioPharma's future outlook is shaped by several forward-looking statements made by the company. These statements reflect the company's expectations, beliefs, and assumptions about future developments and their impact on the business. It is important to consider these statements within the context of associated risks and uncertainties.

Risks include the inherent unpredictability of clinical trials, reliance on third-party funding, patient enrollment challenges, and dependency on executive leadership. These factors, among others, could lead to outcomes that differ significantly from the company's projections.

Conclusion

Mereo BioPharma is committed to advancing treatments for rare diseases through innovation, strategic alliances, and rigorous clinical trials. Their involvement in events like the Jefferies Global Healthcare Conference underscores their dedication to engaging with the medical community and stakeholders.

For more detailed information, visit the company’s website or tune into the webcast on the specified date.